Publications by authors named "E C Mora"
Article Synopsis
- Mutations commonly associated with acute myeloid leukemia (AML) were studied in 127 patients with chronic myelomonocytic leukemia (CMML), revealing varying prevalence rates like CEBPA (7), FLT3 (8), IDH1 (12), IDH2 (26), and NPM1 (11).
- CMML patients with CEBPA, FLT3, and/or NPM1 mutations showed more severe symptoms and higher risk characteristics, indicating they were more frequently linked to the myeloproliferative subtype (MP-CMML).
- The study suggests that these mutations should be included in CMML prognostic models and advocates for treating these patients with AML-type therapies due to their poor
Article Synopsis
- The global push for sustainable waste management encourages the integration of co-digestion methods for sewage and organic waste using anaerobic reactors, promoting environmental and economic benefits for municipalities.
- Numerous studies, from laboratory experiments to large-scale implementations, have explored the potential of this co-treatment, but there's still a lack of a unified definition and understanding of co-digestion's impacts.
- The review highlights how combining organic waste with sewage treatment could significantly boost methane production and improve sustainability, while also identifying challenges like the need for customized strategies and regulatory support.
Two of nature's recurring binding motifs in metalloproteins are the CxxxCxxC motif in radical SAM enzymes and the 2-His-1-carboxylate motif found both in zincins and α-ketoglutarate and non-haem iron enzymes. Here we show the confluence of these two domains in a single post-translational modifying enzyme containing an N-terminal radical S-adenosylmethionine domain fused to a C-terminal 2-His-1-carboxylate (HExxH) domain. The radical SAM domain catalyses three-residue cyclophane formation and is the signature modification of triceptides, a class of ribosomally synthesized and post-translationally modified peptides.
View Article and Find Full Text PDFArticle Synopsis
- Lenalidomide (LEN) can help 60-70% of patients with del(5q) myelodysplastic neoplasm achieve independence from red blood cell transfusions (RBC-TI), but there's a concern about its toxicity and cost.
- The HARMONY Alliance study followed 118 low-intermediate risk MDS patients who discontinued LEN, finding that 50 lost RBC-TI after a median of 49 months.
- Factors like having a low transfusion burden before treatment, completing at least 12 LEN cycles, being younger, and having higher hemoglobin levels at withdrawal were linked to longer RBC-TI duration after discontinuing LEN.